INM: InMed to merge with Mentari Therapeutics, shareholder vote needed
Pending reverse merger with Mentari Therapeutics; 5.49M shares outstanding, shareholder approval and Nasdaq change-of-control vote needed…
What this filing says
InMed agreed to a two-step merger with Mentari Therapeutics, under which Mentari would become a wholly owned subsidiary of InMed. The deal is subject to shareholder approvals, including an issuance of more than 20% of outstanding shares that would change control under Nasdaq rules, and the merger is expected to close in the fourth quarter of 2026. For a shareholder, this means a significant dilution and change in the company's direction if the deal goes through.
Key figures
- Common Shares outstanding
- 5,493,735 shares
- Expected closing
- Fourth quarter of calendar 2026
- Share issuance requiring approval
- More than 20% of outstanding Common Shares
Positive for shareholders
- The merger would bring Mentari into the company as a wholly owned subsidiary, if completed.
Negative for shareholders
- Shareholders must approve an issuance of more than 20% of outstanding shares, which would dilute existing holders.
- The issuance would result in a change of control under Nasdaq rules.
- The merger may be terminated in circumstances that require InMed to pay a termination fee.
- The merger depends on shareholder approvals and closing conditions that have not yet been met.
Written by Quantisnow AI from this filing. Not financial advice.
Key terms
- Two-step merger:
- A deal structure in which one subsidiary merges into the target and the target then merges into a second subsidiary, so the target ends up owned by the buyer.
- Change of control:
- A shift in who controls a company, often triggering Nasdaq shareholder approval requirements when a large share issuance occurs.
- Consolidation of Common Shares:
- A reverse stock split that reduces the number of outstanding shares and typically raises the price per share.
FAQ
What does InMed need shareholders to approve for the Mentari merger?
The filing says shareholders must approve the issuance of Common Shares above 20% of outstanding shares, a potential reduction of capital, and the continuation of the company from British Columbia to Nevada.
When is the InMed and Mentari merger expected to close?
The filing states the merger is expected to close in the fourth quarter of calendar 2026, subject to satisfaction or waiver of closing conditions.
Historical context for INM
Across the 5 sessions after earlier INM headlines, the stock closed higher 3 times and lower 1 times, with a median move of 4.3% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | INM | SPY |
|---|---|---|---|
| Jul 22, 2026 | Mentari Therapeutics Announces $200 Million Private Placement for Migraine Prevention Pipeline | +7.8% | -0.1% |
| Jun 5, 2026 | InMed Pharmaceuticals Regains Compliance with Nasdaq Continued Listing Requirements | +1.3% | -2.6% |
| May 19, 2026 | /C O R R E C T I O N -- InMed Pharmaceuticals/and 1 other headline that session | +135.1% | -0.7% |
| Apr 28, 2026 | InMed Pharmaceuticals Amends Preferred Investment Options | -4.3% | -0.5% |
| Dec 9, 2025 | Life Sciences Virtual Investor Forum Agenda Announced for December 11th | +0.0% | -0.1% |
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
Follow INM and get a push notification the moment its next story breaks.